Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | PTAFR | P25105 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17064309 | 0.89 | CYP2A6 (0.58) | HRH3CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL7427487 | 0.86 | CYP2A6 (0.54) | HRH3CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL7407607 | 0.84 | CYP2A6 (0.53) | HRH3CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL6569542 | 0.84 | CYP2A6 (0.53) | HRH3CYP2A6TDP1L3MBTL1HRH1 | |
| SCHEMBL38663623 | 0.81 | GBA1 (0.62) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL2279484 | 0.81 | GBA1 (0.62) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 | |
| SCHEMBL4325779 | 0.81 | HRH3 (0.54) | HRH3HRH1HRH4SLC6A4GBA1 | |
| SCHEMBL82734 | 0.80 | GBA1 (0.61) | HRH3SLC6A4GBA1 | |
| SCHEMBL5392180 | 0.80 | LMNA (0.55) | PTAFR | |
| Hydrochloric Acid SCHEMBL3301662 | 0.80 | GBA1 (0.61) | CHRM2CHRM1CHRNB2CHRM3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| EP-1833800-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006071730-A1 | PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | CHRM2 103/4885CHRM1 44/4885CHRNB2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.